Degradable microparticles have broad utility as vehicles for drug delivery and form the basis of several FDA-approved therapies. Conventional emulsion-based methods of manufacturing produce particles with a wide range of diameters (and thus kinetics of release) in each batch. This paper describes the fabrication of monodisperse, drug-loaded microparticles from biodegradable polymers using the microfluidic flow-focusing (FF) devices and the drug delivery properties of those particles. Particles were engineered with defined sizes, ranging from 10 μm to 50 μm. These particles were nearly monodisperse (polydispersity index = 3.9 %). We incorporated a model amphiphilic drug (bupivacaine) within the biodegradable matrix of the particles. Kinetic analysis showed that the release of drug from these monodisperse particles was slower than that from conventional methods of the same average size but a broader distribution of sizes and, most importantly, exhibited a significantly lower initial burst than that observed with conventional particles. The difference in the initial kinetics of drug release was attributed to the uniform distribution of drug inside the particles generated using the microfluidic methods. These results demonstrated the utility of microfluidic FF for the generation of homogenous systems of particles for the delivery of drugs.
A central challenge to the development of protein-based therapeutics is the inefficiency of delivery of protein cargo across the mammalian cell membrane, including escape from endosomes. Here we report that combining bioreducible lipid nanoparticles with negatively supercharged Cre recombinase or anionic Cas9:single-guide (sg)RNA complexes drives the electrostatic assembly of nanoparticles that mediate potent protein delivery and genome editing. These bioreducible lipids efficiently deliver protein cargo into cells, facilitate the escape of protein from endosomes in response to the reductive intracellular environment, and direct protein to its intracellular target sites. The delivery of supercharged Cre protein and Cas9:sgRNA complexed with bioreducible lipids into cultured human cells enables gene recombination and genome editing with efficiencies greater than 70%. In addition, we demonstrate that these lipids are effective for functional protein delivery into mouse brain for gene recombination in vivo. Therefore, the integration of this bioreducible lipid platform with protein engineering has the potential to advance the therapeutic relevance of protein-based genome editing.
Although genetic factors contribute to almost half of all deafness cases,
treatment options for genetic deafness are limited1–5. We developed a genome editing approach to target a
dominantly inherited form of genetic deafness. Here we show that cationic
lipid-mediated in vivo delivery of Cas9:guide RNA complexes can
ameliorate hearing loss in a mouse model of human genetic deafness. We designed
and validated in vitro and in primary fibroblasts genome
editing agents that preferentially disrupt the dominant deafness-associated
allele in the Tmc1 (transmembrane channel-like 1) Beethoven
(Bth) mouse model, even though the mutant
Bth allele differs from the wild-type allele at only a
single base pair. Injection of Cas9:guide RNA:lipid complexes targeting the
Bth allele into the cochlea of neonatal
Bth/+ mice substantially reduced progressive
hearing loss. We observed higher hair cell survival rates and lower auditory
brainstem response (ABR) thresholds in injected ears compared with uninjected
ears or ears injected with complexes that target an unrelated gene. Enhanced
acoustic reflex responses were observed among injected compared to uninjected
Bth/+ animals. These findings suggest protein:RNA
complex delivery of target gene-disrupting agents in vivo as a
potential strategy for the treatment of some autosomal dominant hearing loss
diseases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.